Pharm Aid Ltd pharmaceutical company was founded in 2017 with the aim of transferring technologies for the production of innovative biotechnological products to Russia.
Today, Pharm Aid Ltd is Russia’s largest supplier of vaccines for the prevention of rotavirus infection, and the company is implementing a project to build a production site to manufacture innovative combined immunobiological drugs for the prevention and treatment of various diseases in the Vorsino Industrial Park in the Kaluga Region.
Today, Pharm Aid Ltd is Russia’s largest supplier of vaccines for the prevention of rotavirus infection, and the company is implementing a project to build a production site to manufacture innovative combined immunobiological drugs for the prevention and treatment of various diseases in the Vorsino Industrial Park in the Kaluga Region.
OUR VISION
To protect the population of Russia and the CIS with affordable, high-quality medical technologies, making the world’s best biopharmaceuticals available to everyone. In this way, we participate in biopharmaceutical industry development and modernization in Russia in line with Russian Federation’s state strategy to achieve independence from imports of essential medicines.
OUR VALUES
We understand that health matters require expedience, and we strive to bring modern, innovative immunobiological drugs to market and make them affordable so that more people have access to high-quality prevention and therapy.
Collaborating for a better future
We develop international cooperation and localize cutting-edge biotechnology developments in Russia in partnership with the world’s leading pharmaceutical companies. This will guarantees sustainable development and efficient modernization of the domestic pharmaceutical industry and provide the country with new, affordable drugs.
INTERNATIONAL
COLLABORATION
RESEARCH
& DEVELOPMENT
FULL-CYCLE
MANUFACTURING
NEW LOCALLY –
PRODUCED DRUGS
INNOVATIVE, EFFECTIVE, AND AFFORDABLE PRODUCTS
We aim to create full-cycle local development and manufacturing operations for the following vaccines and immunobiological preparations:
- Varicella Vaccine
- Rotavirus Vaccine
- Human Papillomavirus Vaccine
- Meningococcal Vaccine
- Monoclonal Antibody for Rabies
- MMR Vaccine (Measles, Mumps, Rubella)
KEY OBJECTIVES
Our key objectives are:
- Secure best-in-class technology for new, innovative vaccines and immunobiological product pipeline creation.
- Development of a state-of-the-art R&D center and manufacturing plant supported by technology transfer to achieve full-cycle localized production of immunobiological drugs and vaccines in Russia.
- Increase market access to effective and affordable therapies for Russian patients.
PRODUCTION
Creating our own production of pharmaceutical products is our contribution to the implementation of Russian Federation’s state strategy on import substitution of essential drugs.
The modern production complex at the Vorsino Industrial Park in the Kaluga Region aims to produce a wide range of innovative multi-component products using advanced biotechnology.
The plant is designed in accordance with biosafety requirements for handling Group III-IV pathogenic biological agents (WHO: BSL – ½) as well as GMP requirements of Russia and the Eurasian Economic Union.
The complex includes two workshops for the production of live and inactivated vaccines. Both workshops are equipped with highly efficient lines capable of meeting the needs of Russia and the CIS and have flexibility to produce multiple vaccines, which will facilitate production increase in case of an emergency or disease outbreak. The site will also have a quality control laboratory equipped with high-tech equipment with centralized computer control.
The modern production complex at the Vorsino Industrial Park in the Kaluga Region aims to produce a wide range of innovative multi-component products using advanced biotechnology.
The plant is designed in accordance with biosafety requirements for handling Group III-IV pathogenic biological agents (WHO: BSL – ½) as well as GMP requirements of Russia and the Eurasian Economic Union.
The complex includes two workshops for the production of live and inactivated vaccines. Both workshops are equipped with highly efficient lines capable of meeting the needs of Russia and the CIS and have flexibility to produce multiple vaccines, which will facilitate production increase in case of an emergency or disease outbreak. The site will also have a quality control laboratory equipped with high-tech equipment with centralized computer control.
FEATURES
50,000 sq. m.
Plant Area
> 25,000 sq. m.
Future Plant Area
up to 13,000,000 doses of vaccines
annual production capacity